白云山：子公司注射用头孢他啶通过一致性评价

Core Viewpoint - Recently, the company announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the supplementary application of injectable Cefotaxime (0.5g, 1.0g), which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The company has a significant development in its pharmaceutical segment with the approval of injectable Cefotaxime [1] - The approval indicates the company's commitment to enhancing its product portfolio and meeting regulatory standards [1] - This development may lead to increased market competitiveness for the company's pharmaceutical products [1]